Select Language
CNR1
CNR1 Overview
| English Name | Cannabinoid CB1 receptor | Approved Drugs | 2 |
| Drugs in Clinical Trials | 38 | Target Synonym | Cannabinoid Receptor 1 (Brain)，CNR1，Cannabinoid Receptor 1，CANN6，CB-R，CNR，CB1，Central Cannabinoid Receptor，CB1K5，CB1A，CB1R，Receptor， Cannabinoid， CB1 |
| Highest Development Stage | Approved | ||
| English Name | Cannabinoid CB1 receptor |
| Target Synonym | Cannabinoid Receptor 1 (Brain)，CNR1，Cannabinoid Receptor 1，CANN6，CB-R，CNR，CB1，Central Cannabinoid Receptor，CB1K5，CB1A，CB1R，Receptor， Cannabinoid， CB1 |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 38 |
| Highest Development Stage | Approved |
CNR1 Product List
- Product Category
Protein (3)
- Product Status
Launched (3)
- Species
Human (3)
- Tag
- (1)His Tag & Flag Tag (1)His Tag & Avi Tag & Flag Tag (1)
- Conjugate
Unconjugated (2)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
CN1-H52P6 |  Human | HEK293 | Human CNR1 Full Length Protein (VLP) |  | ||
CN1-H55D3 | Human | InsectCells | Human CNR1 Protein, Flag,His Tag (Detergent) |  |  | |
CN1-H85D3 | Human | InsectCells | Biotinylated Human CNR1 Protein, Flag Tag&His,Avitag™ (Detergent) | | |
Total: 3
- 1
CNR1 Background
This gene encodes one of two cannabinoid receptors. The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene. [provided by RefSeq, May 2009]
CNR1 Synonyms
CNR1,cannabinoid receptor 1,CANN6, CB-R, CB1, CB1A, CB1K5, CB1R, CNR
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotechnologies Inc | Anorexia Nervosa; Cachexia; Child Nutrition Disorders; Nausea; Neoplasms; Nutrition Disorders; Sarcopenia; Vomiting | Details | |
| Cannabidiol soft-gel (Avecho Biotechnology) | CBD-TPM | Phase 3 Clinical | Avecho Biotechnology Ltd | Sleep Initiation and Maintenance Disorders | Details |
| Cannabidiol Gel (Zynerba) | ZYN002; ZYN-002 | Phase 3 Clinical | Zynerba Pharmaceuticals Inc | DiGeorge Syndrome; Fragile X Syndrome | Details |
| Adezunap | AP-707 | Phase 3 Clinical | CannaXan GmbH | Accidental Injuries; Back Pain; Brachial Plexus Neuropathies; Brain Injuries, Traumatic; Chronic Pain; Diabetes Mellitus; Diabetic Neuropathies; Diabetic peripheral neuropathy; Low Back Pain; Multiple Sclerosis; Neuralgia; Pain; Pain, Postoperative; Paraplegia; Peripheral Nerve Injuries; Peripheral Nervous System Diseases; Phantom Limb; Somatoform Disorders; Stroke | Details |
| Dronabinol（Vertanical） | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | Details |
| cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Myocarditis; Pericarditis | Details | |
| Selonabant | V-24343; ANEB-001; VER-24343 | Phase 2 Clinical | Vernalis Plc | Obesity; Poisoning | Details |
| 11C-MePPEP | 11C-MePPEP | Phase 2 Clinical | Eli Lilly And Company | Obesity; Substance-Related Disorders | Details |
| AX-1602 | AX-1602 | Phase 2 Clinical | Axim Biotechnologies Inc | Dermatitis, Atopic; Psoriasis; Vitiligo | Details |
| Nimacimab | RYI-018; RYI-028; JNJ-2463 | Phase 2 Clinical | Bird Rock Bio Inc | Diabetic Gastroparesis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Renal Insufficiency, Chronic | Details |
| ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Anorexia; Cachexia; Low Back Pain; Pain; Weight Loss | Details |
| AEF-0217 | AEF-0217 | Phase 2 Clinical | Aelis Farma | Down Syndrome | Details |
| Monlunabant | S-MRI-1891; (-)-MRI-1891; NN9440–INV-202; INV-202; MRI-1891 | Phase 2 Clinical | Inversago Pharma Inc | Diabetic Nephropathies; Metabolic Diseases; Metabolic Syndrome; Obesity | Details |
| Cannabidiol (Ananda Scientific) | A-1002-N5S; A1002N5S | Phase 2 Clinical | Ananda Scientific Inc | Chronic Pain; Opioid-Related Disorders; Stress Disorders, Post-Traumatic; Tobacco Smoking; Tobacco Use Disorder | Details |
| Cannabidiol (Biopharmaceutical Research Company) | BRC-001 | Phase 2 Clinical | Biopharmaceutical Research Company | Breast Neoplasms; Carcinoma, Ductal, Breast | Details |
| C20T5 | C20T5 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| C12T12 | C12T12 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| Suvadronabinol | THC-VHS-NEC; SBI-100; NB-1111; Sb-100 OE; SBI-100 OE; THCVHS; THCVHS-N; THCVHS-NE; UM-5050 | Phase 2 Clinical | University Of Mississippi | Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension | Details |
| IGC-AD1 | IGC-AD1 | Phase 2 Clinical | University Of South Florida | Alzheimer Disease; Dementia; Psychomotor Agitation | Details |
| Lixosicone | AEF-0117 | Phase 2 Clinical | Aelis Farma, National Institute On Drug Abuse | Marijuana Abuse | Details |
| ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Fibromyalgia; Neuralgia | Details |
| Tetrahydrocannabivarin | GWP-42004; THCV; O-4394; DELTA9-THCV; GW-42004 | Phase 1 Clinical | Gw Pharmaceuticals Plc | Diabetes Mellitus, Type 2; Dyslipidemias; Hypercholesterolemia; Hyperglycemia; Metabolic Syndrome; Obesity, Morbid | Details |
| Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 1 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | Details |
| Zevaquenabant | MRI-1867; (S)-MRI-1867; INV-101 | Phase 1 Clinical | National Institutes Of Health | Scleroderma, Systemic | Details |
| Cannabidiol (Artelo Biosciences) | ART-12.11; ART12.11; ART-1211 | Phase 1 Clinical | Artelo Biosciences Inc | Anxiety; Depression; Depressive Disorder | Details |
| S1-221 | S1-221 | Phase 1 Clinical | Delphian Therapeutics Australia Pty Ltd | Details | |
| Cannabidiol (Tiamat Australia) | MRX-1 | Phase 1 Clinical | Tiamat Australia Pty Ltd | Details | |
| Atorvastatin Calcium Hydrate/Cannabidiol | Phase 1 Clinical | Indication Bioscience LLC | Coronary Disease; Dyslipidemias | Details | |
| TPT0301 | TPT-0301; TPT0301 | Phase 1 Clinical | Tetra Pharm Technologies ApS | Chronic Pain | Details |
| INV-347 | NN9441; NN-9441; INV-347 | Phase 1 Clinical | Inversago Pharma Inc | Obesity | Details |
| IPI 201（Isosceles Pharmaceuticals Inc ） | IPI-201 | Phase 1 Clinical | Pain, Postoperative | Details | |
| CRB-913 | CRB-913 | Phase 1 Clinical | Jenrin Discovery LLC | Obesity | Details |
| GFB-024 | Phase 1 Clinical | Takeda Pharma | Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Endocrine System Diseases; Kidney Diseases | Details | |
| DBPR-211 | Phase 1 Clinical | National Health Research Institutes | Diabetes Mellitus, Type 2 | Details | |
| MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | Details |
| MP-20X | MP-20X | Clinical | Medipure Holdings | Anxiety Disorders; Mood Disorders | Details |
| Cannabidiol (Receptor Life Sciences) | Clinical | Receptor Life Sciences Inc | Autism Spectrum Disorder | Details | |
| Cannabidiol/Palmitoylethanolamide | SCI–210; THX-210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cannabidiol/Dronabinol | delta-9-THC/CBD; MPL-001; MPL-005; PPP-011; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT; GW-1000; KL16-012; THC-5 | Approved | Gw Pharmaceuticals | Sativex, Qixleef, QIXLEEFTM | Canada | Cancer Pain; Chronic Pain; Muscle Spasticity; Neuralgia; Multiple Sclerosis | null | 2005-04-01 | Acute Pain; Agitation; Agoraphobia; Anorexia; Anxiety Disorders; Arthritis, Psoriatic; Arthritis, Rheumatoid; Back Pain; Cancer Pain; Cerebral Palsy; Chronic Pain; Corticobasal degeneration; Dementia; Depression; Depressive Disorder, Major; Diabetic Neuropathies; Drug Resistant Epilepsy; Essential Tremor; Genital Diseases, Male; Healthy Aging; Hepatic Insufficiency; Hidradenitis Suppurativa; Huntington Disease; Kidney Diseases; Low Back Pain; Malnutrition; Marijuana Abuse; Marijuana Use; Migraine Disorders; Multiple Sclerosis; Muscle Spasticity; Neck Pain; Neoplasms; Neuralgia; Neuralgia, Postherpetic; Neuromyelitis Optica; Opioid-Related Disorders; Osteoarthritis, Knee; Pain; Panic Disorder; Peripheral Nervous System Diseases; Phobia, Social; Psoriasis; Reflex Sympathetic Dystrophy; Renal Insufficiency; Renal Insufficiency, Chronic; Sciatica; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Social Behavior; Spasm; Spinal Cord Injuries; Squamous Cell Carcinoma of Head and Neck; Stress Disorde | Details |
| Cannabidiol | CHI-902; APH-1501; GLA-015; BTX-1503; BTX-1801; GWP-42003-P; BOL-DP-o-05; GW-42003; BTX-1204; PTL-101; BTX-1702; PBX-1308; BRCX-014; LYT-310; GWP-42003 | Approved | Gw Pharmaceuticals Plc | Epidyolex, Cannepil, Epidiolex | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Acne Vulgaris; Acute Pain; Alcohol Abstinence; Alcoholic Intoxication; Alcoholism; Anemia, Sickle Cell; Anorexia Nervosa; Anxiety; Anxiety Disorders; Appetitive Behavior; Arthralgia; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autism Spectrum Disorder; Autistic Disorder; Azotemia; Behavior, Addictive; Bipolar Disorder; Blepharospasm; Brain Diseases; Brain Injuries, Traumatic; Breast Neoplasms; Bruxism; Burnout, Psychological; Cachexia; Carcinoma, Non-Small-Cell Lung; Carpal Tunnel Syndrome; Central Nervous System Diseases; Child Behavior Disorders; Chronic Pain; Chronic Periodontitis; Chronic Urticaria; Cicatrix; Cognition Disorders; Cognitive Dysfunction; Colitis, Ulcerative; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Corticobasal degeneration; Craving; Crohn Disease; Cystitis, Interstitial; Dentin Sensitivity; Depression; Dermatitis, Atopic; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Driving Under the Influence; Drug Resistant Epilepsy; Dyslipidemias; Dysmenorrhea; Dyspepsia; Eczema; | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호